Dapagliflozin – Medgate Today

AstraZeneca’s Dapagliflozin gets additional indication approval for treatment of Heart Failure in adults in India

July 26, 2023

7:58 am

The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca AstraZeneca Pharma India Ltd. (AstraZeneca India), a science-led biopharmaceutical company, announced it has received extended indication approval from the Drugs Controller General of India

POST TAGS:

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

September 9, 2022

6:34 am

News Update

admin

Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64

POST TAGS:

AstraZeneca BioPharmaceuticals Dapagliflozin Dr. Anil Kukreja Dr. VK Chopra Health Max Super Speciality Hospital

AstraZeneca’s Dapagliflozin gets additional indication approval for treatment of Heart Failure in adults in India

POST TAGS:

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA